240 related articles for article (PubMed ID: 31101622)
1. Recurrent
Luchtel RA; Zimmermann MT; Hu G; Dasari S; Jiang M; Oishi N; Jacobs HK; Zeng Y; Hundal T; Rech KL; Ketterling RP; Lee JH; Eckloff BW; Yan H; Gaonkar KS; Tian S; Ye Z; Kadin ME; Sidhu J; Jiang L; Voss J; Link BK; Syrbu SI; Facchetti F; Bennani NN; Slager SL; Ordog T; Kocher JP; Cerhan JR; Ansell SM; Feldman AL
Blood; 2019 Jun; 133(26):2776-2789. PubMed ID: 31101622
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with
Luchtel RA; Dasari S; Oishi N; Pedersen MB; Hu G; Rech KL; Ketterling RP; Sidhu J; Wang X; Katoh R; Dogan A; Kip NS; Cunningham JM; Sun Z; Baheti S; Porcher JC; Said JW; Jiang L; Hamilton-Dutoit SJ; Møller MB; Nørgaard P; Bennani NN; Chng WJ; Huang G; Link BK; Facchetti F; Cerhan JR; d'Amore F; Ansell SM; Feldman AL
Blood; 2018 Sep; 132(13):1386-1398. PubMed ID: 30093402
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G;
Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034
[TBL] [Abstract][Full Text] [Related]
4. JAK/STAT3 Signaling Activation Related to Distinct Clinicopathologic Features in Systemic ALK - Anaplastic Large Cell Lymphomas : New Insights into Their Heterogeneity.
Wang JC; Zhong LH; Lin WQ; Zhang WF; Xi YF; Liu YP; Zhu Q; Liu W; Zhu WF; Chen YP; Chen G
Am J Surg Pathol; 2023 Jan; 47(1):55-64. PubMed ID: 36315833
[TBL] [Abstract][Full Text] [Related]
5. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.
Parrilla Castellar ER; Jaffe ES; Said JW; Swerdlow SH; Ketterling RP; Knudson RA; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Vasmatzis G; Gibson SE; Ondrejka S; Nicolae A; Grogg KL; Allmer C; Ristow KM; Wilson WH; Macon WR; Law ME; Cerhan JR; Habermann TM; Ansell SM; Dogan A; Maurer MJ; Feldman AL
Blood; 2014 Aug; 124(9):1473-80. PubMed ID: 24894770
[TBL] [Abstract][Full Text] [Related]
6. Genetics of anaplastic large cell lymphoma.
Zeng Y; Feldman AL
Leuk Lymphoma; 2016; 57(1):21-7. PubMed ID: 26104084
[TBL] [Abstract][Full Text] [Related]
7. Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.
King RL; Dao LN; McPhail ED; Jaffe ES; Said J; Swerdlow SH; Sattler CA; Ketterling RP; Sidhu JS; Hsi ED; Karikehalli S; Jiang L; Gibson SE; Ondrejka SL; Nicolae A; Macon WR; Dasari S; Parrilla Castellar E; Feldman AL
Am J Surg Pathol; 2016 Jan; 40(1):36-43. PubMed ID: 26379151
[TBL] [Abstract][Full Text] [Related]
8. ALK-Negative Anaplastic Large Cell Lymphoma (ALCL): Prognostic Implications of Molecular Subtyping and JAK-STAT Pathway.
Parkhi M; Bal A; Das A; Kashyap D; Bhardwaj S; Prakash G; Malhotra P
Appl Immunohistochem Mol Morphol; 2021 Oct; 29(9):648-656. PubMed ID: 33901030
[TBL] [Abstract][Full Text] [Related]
9. Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma.
Weilemann A; Grau M; Erdmann T; Merkel O; Sobhiafshar U; Anagnostopoulos I; Hummel M; Siegert A; Hayford C; Madle H; Wollert-Wulf B; Fichtner I; Dörken B; Dirnhofer S; Mathas S; Janz M; Emre NC; Rosenwald A; Ott G; Lenz P; Tzankov A; Lenz G
Blood; 2015 Jan; 125(1):124-32. PubMed ID: 25359993
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.
Xing X; Feldman AL
Adv Anat Pathol; 2015 Jan; 22(1):29-49. PubMed ID: 25461779
[TBL] [Abstract][Full Text] [Related]
11. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.
Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW
Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573
[TBL] [Abstract][Full Text] [Related]
12. ALCL by any other name: the many facets of anaplastic large cell lymphoma.
Irshaid L; Xu ML
Pathology; 2020 Jan; 52(1):100-110. PubMed ID: 31706671
[TBL] [Abstract][Full Text] [Related]
13. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
15. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
Kutok JL; Aster JC
J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
[TBL] [Abstract][Full Text] [Related]
16. miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells.
Hoareau-Aveilla C; Quelen C; Congras A; Caillet N; Labourdette D; Dozier C; Brousset P; Lamant L; Meggetto F
Haematologica; 2019 Feb; 104(2):347-359. PubMed ID: 30262555
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.
Merkel O; Hamacher F; Griessl R; Grabner L; Schiefer AI; Prutsch N; Baer C; Egger G; Schlederer M; Krenn PW; Hartmann TN; Simonitsch-Klupp I; Plass C; Staber PB; Moriggl R; Turner SD; Greil R; Kenner L
J Pathol; 2015 Aug; 236(4):445-56. PubMed ID: 25820993
[TBL] [Abstract][Full Text] [Related]
18. Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma.
Ravindran A; Feldman AL; Ketterling RP; Dasari S; Rech KL; McPhail ED; Kurtin PJ; Shi M
Am J Surg Pathol; 2021 Apr; 45(4):550-557. PubMed ID: 33165091
[TBL] [Abstract][Full Text] [Related]
19. Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.
Xing X; Flotte TJ; Law ME; Blahnik AJ; Chng WJ; Huang G; Knudson RA; Ketterling RP; Porcher JC; Ansell SM; Sidhu J; Dogan A; Feldman AL
Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):580-9. PubMed ID: 25390351
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
